PDCD1 and cancer: After the notable achievements for cancer therapy by the use of blocking the CTLA-4 and PD-1, which are the first detected immune checkpoints, a new surge of explorations for cancer therapy based on the blocking of immune checkpoint ligands and receptors, was emerged [10].